Israeli startup DayTwo, a company that has developed a personalized health platform based on the gut microbiome, has announced it has raised $31 million in a Series B funding round, led by Israel-based aMoon fund and Ofek Ventures, a fund founded by Magma Venture Partners co-founder Yahel Zilka.
The round also had participation from previous investors including Johnson & Johnson, Seventure Partners, and Israeli NBA basketball player Omri Casspi, as well as other private investors.
The company has raised $48 million to date.
DayTwo’s platform currently provides customized diet recommendations through a mobile phone app that helps balance blood sugar. While the app is intended for the average consumer, it also offers solutions for those with Type II diabetes.
The startup was founded in 2015 by Lihi Segal, who has held senior roles in a number of businesses and has an LLB from Tel Aviv University and an MBA from Northwestern University.
The company’s solutions are based on research conducted by Professors Eran Segal, Ph.D., and Eran Elinav, M.D., Ph.D. at The Weizmann Institute of Science published in 2015.
The new capital will be used to increase workers in the Tel Aviv office in the coming year.